Advertisement
| data science in drug discovery: The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry Stephanie K. Ashenden, 2021-04-23 The Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry examines the drug discovery process, assessing how new technologies have improved effectiveness. Artificial intelligence and machine learning are considered the future for a wide range of disciplines and industries, including the pharmaceutical industry. In an environment where producing a single approved drug costs millions and takes many years of rigorous testing prior to its approval, reducing costs and time is of high interest. This book follows the journey that a drug company takes when producing a therapeutic, from the very beginning to ultimately benefitting a patient's life. This comprehensive resource will be useful to those working in the pharmaceutical industry, but will also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics. - Demonstrates how the prediction of toxic effects is performed, how to reduce costs in testing compounds, and its use in animal research - Written by the industrial teams who are conducting the work, showcasing how the technology has improved and where it should be further improved - Targets materials for a better understanding of techniques from different disciplines, thus creating a complete guide |
| data science in drug discovery: Lattice Deepayan Sarkar, 2008-02-15 Written by the author of the lattice system, this book describes lattice in considerable depth, beginning with the essentials and systematically delving into specific low levels details as necessary. No prior experience with lattice is required to read the book, although basic familiarity with R is assumed. The book contains close to 150 figures produced with lattice. Many of the examples emphasize principles of good graphical design; almost all use real data sets that are publicly available in various R packages. All code and figures in the book are also available online, along with supplementary material covering more advanced topics. |
| data science in drug discovery: Data Science, AI, and Machine Learning in Drug Development Harry Yang, 2022-10-04 The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations. Features Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise |
| data science in drug discovery: Artificial Intelligence in Drug Discovery Nathan Brown, 2020-11-04 Following significant advances in deep learning and related areas interest in artificial intelligence (AI) has rapidly grown. In particular, the application of AI in drug discovery provides an opportunity to tackle challenges that previously have been difficult to solve, such as predicting properties, designing molecules and optimising synthetic routes. Artificial Intelligence in Drug Discovery aims to introduce the reader to AI and machine learning tools and techniques, and to outline specific challenges including designing new molecular structures, synthesis planning and simulation. Providing a wealth of information from leading experts in the field this book is ideal for students, postgraduates and established researchers in both industry and academia. |
| data science in drug discovery: Drug Discovery and Development - E-Book Raymond G Hill, 2012-07-20 The modern pharmacopeia has enormous power to alleviate disease, and owes its existence almost entirely to the work of the pharmaceutical industry. This book provides an introduction to the way the industry goes about the discovery and development of new drugs. The first part gives a brief historical account from its origins in the mediaeval apothecaries' trade, and discusses the changing understanding of what we mean by disease, and what therapy aims to achieve, as well as summarising case histories of the discovery and development of some important drugs. The second part focuses on the science and technology involved in the discovery process: the stages by which a promising new chemical entity is identified, from the starting point of a medical need and an idea for addressing it. A chapter on biopharmaceuticals, whose discovery and development tend to follow routes somewhat different from synthetic compounds, is included here, as well as accounts of patent issues that arise in the discovery phase, and a chapter on research management in this environment. The third section of the book deals with drug development: the work that has to be undertaken to turn the drug candidate that emerges from the discovery process into a product on the market. - The definitive introduction to how a pharmaceutical company goes about its business of discovering and developing drugs. The second edition has a new editor: Professor Raymond Hill ● non-executive director of Addex Pharmaceuticals, Covagen and of Orexo AB ● Visiting Industrial Professor of Pharmacology in the University of Bristol ● Visiting Professor in the School of Medical and Health Sciences at the University of Surrey ● Visiting Professor in Physiology and Pharmacology at the University of Strathclyde ● President and Chair of the Council of the British Pharmacological Society ● member of the Nuffield Council on Bioethics and the Advisory Council on Misuse of Drugs. New to this edition: - Completely rewritten chapter on The Role of Medicinal Chemistry in the Drug Discovery Process. - New topic - DMPK Optimization Strategy in drug discovery. - New chapter on Scaffolds: Small globular proteins as antibody substitutes. - Totally updated chapters on Intellectual Property and Marketing - 50 new illustrations in full colour Features - Accessible, general guide to pharmaceutical research and development. - Examines the interfaces between cost and social benefit, quality control and mass production, regulatory bodies, patent management, and all interdisciplinary intersections essential to effective drug development. - Written by a strong team of scientists with long experience in the pharmaceutical industry. - Solid overview of all the steps from lab bench to market in an easy-to-understand way which will be accessible to non-specialists. From customer reviews of the previous edition: '... it will have everything you need to know on this module. Deeply referenced and, thus, deeply reliable. - Highly Commended in the medicine category of the BMA 2006 medical book competition - Winner of the Royal Society of Medicine Library Prize for Medical Book of the Year |
| data science in drug discovery: Data Science and Medical Informatics in Healthcare Technologies Nguyen Thi Dieu Linh, Zhongyu (Joan) Lu, 2021-06-19 This book highlights a timely and accurate insight at the endeavour of the bioinformatics and genomics clinicians from industry and academia to address the societal needs. The contents of the book unearth the lacuna between the medication and treatment in the current preventive medicinal and pharmaceutical system. It contains chapters prepared by experts in life sciences along with data scientists for examining the circumstances of health care system for the next decade. It also highlights the automated processes for analyzing data in clinical trial research, specifically for drug development. Additionally, the data science solutions provided in this book help pharmaceutical companies to improve on what had historically been manual, costly and laborious process for cross-referencing research in clinical trials on drug development, while laying the groundwork for use with a full range of other drugs for the conditions ranging from tuberculosis, to diabetes, to heart attacks and many others. |
| data science in drug discovery: Basic Principles of Drug Discovery and Development Benjamin E. Blass, 2021-03-30 Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, which requires a multidisciplinary team approach with input from medicinal chemists, biologists, pharmacologists, drug metabolism experts, toxicologists, clinicians, and a host of experts from numerous additional fields. Enabling technologies such as high throughput screening, structure-based drug design, molecular modeling, pharmaceutical profiling, and translational medicine are critical to the successful development of marketable therapeutics. Given the wide range of disciplines and techniques that are required for cutting edge drug discovery and development, a scientist must master their own fields as well as have a fundamental understanding of their collaborator's fields. This book bridges the knowledge gaps that invariably lead to communication issues in a new scientist's early career, providing a fundamental understanding of the various techniques and disciplines required for the multifaceted endeavor of drug research and development. It provides students, new industrial scientists, and academics with a basic understanding of the drug discovery and development process. The fully updated text provides an excellent overview of the process and includes chapters on important drug targets by class, in vitro screening methods, medicinal chemistry strategies in drug design, principles of in vivo pharmacokinetics and pharmacodynamics, animal models of disease states, clinical trial basics, and selected business aspects of the drug discovery process. - Provides a clear explanation of how the pharmaceutical industry works, as well as the complete drug discovery and development process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property - Includes a new chapter on the discovery and development of biologics (antibodies proteins, antibody/receptor complexes, antibody drug conjugates), a growing and important area of the pharmaceutical industry landscape - Features a new section on formulations, including a discussion of IV formulations suitable for human clinical trials, as well as the application of nanotechnology and the use of transdermal patch technology for drug delivery - Updated chapter with new case studies includes additional modern examples of drug discovery through high through-put screening, fragment-based drug design, and computational chemistry |
| data science in drug discovery: Genomics in Drug Discovery and Development Dimitri Semizarov, Eric Blomme, 2008-11-03 Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists. |
| data science in drug discovery: Advances in Artificial Intelligence, Computation, and Data Science Tuan D. Pham, Hong Yan, Muhammad W. Ashraf, Folke Sjöberg, 2021-07-12 Artificial intelligence (AI) has become pervasive in most areas of research and applications. While computation can significantly reduce mental efforts for complex problem solving, effective computer algorithms allow continuous improvement of AI tools to handle complexity—in both time and memory requirements—for machine learning in large datasets. Meanwhile, data science is an evolving scientific discipline that strives to overcome the hindrance of traditional skills that are too limited to enable scientific discovery when leveraging research outcomes. Solutions to many problems in medicine and life science, which cannot be answered by these conventional approaches, are urgently needed for society. This edited book attempts to report recent advances in the complementary domains of AI, computation, and data science with applications in medicine and life science. The benefits to the reader are manifold as researchers from similar or different fields can be aware of advanced developments and novel applications that can be useful for either immediate implementations or future scientific pursuit. Features: Considers recent advances in AI, computation, and data science for solving complex problems in medicine, physiology, biology, chemistry, and biochemistry Provides recent developments in three evolving key areas and their complementary combinations: AI, computation, and data science Reports on applications in medicine and physiology, including cancer, neuroscience, and digital pathology Examines applications in life science, including systems biology, biochemistry, and even food technology This unique book, representing research from a team of international contributors, has not only real utility in academia for those in the medical and life sciences communities, but also a much wider readership from industry, science, and other areas of technology and education. |
| data science in drug discovery: Data Science Applied to Sustainability Analysis Jennifer Dunn, Prasanna Balaprakash, 2021-05-11 Data Science Applied to Sustainability Analysis focuses on the methodological considerations associated with applying this tool in analysis techniques such as lifecycle assessment and materials flow analysis. As sustainability analysts need examples of applications of big data techniques that are defensible and practical in sustainability analyses and that yield actionable results that can inform policy development, corporate supply chain management strategy, or non-governmental organization positions, this book helps answer underlying questions. In addition, it addresses the need of data science experts looking for routes to apply their skills and knowledge to domain areas. - Presents data sources that are available for application in sustainability analyses, such as market information, environmental monitoring data, social media data and satellite imagery - Includes considerations sustainability analysts must evaluate when applying big data - Features case studies illustrating the application of data science in sustainability analyses |
| data science in drug discovery: Improving and Accelerating Therapeutic Development for Nervous System Disorders Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, 2014-02-06 Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials. |
| data science in drug discovery: Data Mining for Business Analytics Galit Shmueli, Peter C. Bruce, Nitin R. Patel, 2016-04-18 An applied approach to data mining and predictive analytics with clear exposition, hands-on exercises, and real-life case studies. Readers will work with all of the standard data mining methods using the Microsoft® Office Excel® add-in XLMiner® to develop predictive models and learn how to obtain business value from Big Data. Featuring updated topical coverage on text mining, social network analysis, collaborative filtering, ensemble methods, uplift modeling and more, the Third Edition also includes: Real-world examples to build a theoretical and practical understanding of key data mining methods End-of-chapter exercises that help readers better understand the presented material Data-rich case studies to illustrate various applications of data mining techniques Completely new chapters on social network analysis and text mining A companion site with additional data sets, instructors material that include solutions to exercises and case studies, and Microsoft PowerPoint® slides https://www.dataminingbook.com Free 140-day license to use XLMiner for Education software Data Mining for Business Analytics: Concepts, Techniques, and Applications in XLMiner®, Third Edition is an ideal textbook for upper-undergraduate and graduate-level courses as well as professional programs on data mining, predictive modeling, and Big Data analytics. The new edition is also a unique reference for analysts, researchers, and practitioners working with predictive analytics in the fields of business, finance, marketing, computer science, and information technology. Praise for the Second Edition ...full of vivid and thought-provoking anecdotes... needs to be read by anyone with a serious interest in research and marketing.– Research Magazine Shmueli et al. have done a wonderful job in presenting the field of data mining - a welcome addition to the literature. – ComputingReviews.com Excellent choice for business analysts...The book is a perfect fit for its intended audience. – Keith McCormick, Consultant and Author of SPSS Statistics For Dummies, Third Edition and SPSS Statistics for Data Analysis and Visualization Galit Shmueli, PhD, is Distinguished Professor at National Tsing Hua University’s Institute of Service Science. She has designed and instructed data mining courses since 2004 at University of Maryland, Statistics.com, The Indian School of Business, and National Tsing Hua University, Taiwan. Professor Shmueli is known for her research and teaching in business analytics, with a focus on statistical and data mining methods in information systems and healthcare. She has authored over 70 journal articles, books, textbooks and book chapters. Peter C. Bruce is President and Founder of the Institute for Statistics Education at www.statistics.com. He has written multiple journal articles and is the developer of Resampling Stats software. He is the author of Introductory Statistics and Analytics: A Resampling Perspective, also published by Wiley. Nitin R. Patel, PhD, is Chairman and cofounder of Cytel, Inc., based in Cambridge, Massachusetts. A Fellow of the American Statistical Association, Dr. Patel has also served as a Visiting Professor at the Massachusetts Institute of Technology and at Harvard University. He is a Fellow of the Computer Society of India and was a professor at the Indian Institute of Management, Ahmedabad for 15 years. |
| data science in drug discovery: Artificial Intelligence for Drug Development, Precision Medicine, and Healthcare Mark Chang, 2020-05-12 Artificial Intelligence for Drug Development, Precision Medicine, and Healthcare covers exciting developments at the intersection of computer science and statistics. While much of machine-learning is statistics-based, achievements in deep learning for image and language processing rely on computer science’s use of big data. Aimed at those with a statistical background who want to use their strengths in pursuing AI research, the book: · Covers broad AI topics in drug development, precision medicine, and healthcare. · Elaborates on supervised, unsupervised, reinforcement, and evolutionary learning methods. · Introduces the similarity principle and related AI methods for both big and small data problems. · Offers a balance of statistical and algorithm-based approaches to AI. · Provides examples and real-world applications with hands-on R code. · Suggests the path forward for AI in medicine and artificial general intelligence. As well as covering the history of AI and the innovative ideas, methodologies and software implementation of the field, the book offers a comprehensive review of AI applications in medical sciences. In addition, readers will benefit from hands on exercises, with included R code. |
| data science in drug discovery: Bioinformatics and Drug Discovery Richard S. Larson, 2012 Recent advances in drug discovery have been rapid. The second edition of Bioinformatics and Drug Discovery has been completely updated to include topics that range from new technologies in target identification, genomic analysis, cheminformatics, protein analysis, and network or pathway analysis. Each chapter provides an extended introduction that describes the theory and application of the technology. In the second part of each chapter, detailed procedures related to the use of these technologies and software have been incorporated. Written in the highly successful Methods in Molecular Biology series format, the chapters include the kind of detailed description and implementation advice that is crucial for getting optimal results in the laboratory. Thorough and intuitive, Bioinformatics and Drug Discovery, Second Edition seeks to aid scientists in the further study of the rapidly expanding field of drug discovery. |
| data science in drug discovery: The Science and Business of Drug Discovery Edward D. Zanders, 2011-07-08 The Science and Business of Drug Discovery is written for those who want to learn about the biopharmaceutical industry and its products whatever their level of technical knowledge. Its aim is to demystify the jargon used in drug development, but in a way that avoids over simplification and the resulting loss of key information. Each of the nineteen chapters is illustrated with figures and tables which clarify some of the more technical points being made. Also included is a drug discovery case history which draws the relevant material together into a single chapter. In recognizing that it is difficult to navigate through the many external resources dealing with drug development, the book has been written to guide the reader towards the most appropriate information sources, including those listed in the two appendices. The following topics are covered: Different types of drugs: from small molecules to stem cells Background to chemistry of small and large molecules Historical background to drug discovery, pharmacology and biotechnology The drug discovery pipeline: from target discovery to marketed medicine Commercial aspects of drug discovery Challenges to the biopharmaceutical industry and its responses Material of specific interest to technology transfer executives, recruiters and pharmaceutical translators. |
| data science in drug discovery: Deep Learning for the Life Sciences Bharath Ramsundar, Peter Eastman, Patrick Walters, Vijay Pande, 2019-04-10 Deep learning has already achieved remarkable results in many fields. Now it’s making waves throughout the sciences broadly and the life sciences in particular. This practical book teaches developers and scientists how to use deep learning for genomics, chemistry, biophysics, microscopy, medical analysis, and other fields. Ideal for practicing developers and scientists ready to apply their skills to scientific applications such as biology, genetics, and drug discovery, this book introduces several deep network primitives. You’ll follow a case study on the problem of designing new therapeutics that ties together physics, chemistry, biology, and medicine—an example that represents one of science’s greatest challenges. Learn the basics of performing machine learning on molecular data Understand why deep learning is a powerful tool for genetics and genomics Apply deep learning to understand biophysical systems Get a brief introduction to machine learning with DeepChem Use deep learning to analyze microscopic images Analyze medical scans using deep learning techniques Learn about variational autoencoders and generative adversarial networks Interpret what your model is doing and how it’s working |
| data science in drug discovery: Sharing Clinical Trial Data Institute of Medicine, Board on Health Sciences Policy, Committee on Strategies for Responsible Sharing of Clinical Trial Data, 2015-04-20 Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients. |
| data science in drug discovery: Data Science, AI, and Machine Learning in Drug Development Harry Yang, 2022-10 The confluence of big data, AI, and machine learning has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R&D, emerging applications of big data, AI and machine learning in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations. Features Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and machine learning in the entire spectrum of drug R&D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides detailed description of solutions suitable for practitioners with limited data science expertise |
| data science in drug discovery: Applied Big Data Analytics and Its Role in COVID-19 Research Peng Zhao, Xi Chen, 2022 This book provides emerging research on the development and implementation of real-world cases in big data analytics for various industrial and public sections including healthcare, business, social media, and government by highlighting topics such as data processing, deep learning, statistical inference, data visualization, and decision support systems-- |
| data science in drug discovery: Knowledge Modelling and Big Data Analytics in Healthcare Mayuri Mehta, Kalpdrum Passi, Indranath Chatterjee, Rajan Patel, 2021-12-08 Knowledge Modelling and Big Data Analytics in Healthcare: Advances and Applications focuses on automated analytical techniques for healthcare applications used to extract knowledge from a vast amount of data. It brings together a variety of different aspects of the healthcare system and aids in the decision-making processes for healthcare professionals. The editors connect four contemporary areas of research rarely brought together in one book: artificial intelligence, big data analytics, knowledge modelling, and healthcare. They present state-of-the-art research from the healthcare sector, including research on medical imaging, healthcare analysis, and the applications of artificial intelligence in drug discovery. This book is intended for data scientists, academicians, and industry professionals in the healthcare sector. |
| data science in drug discovery: Approaching (Almost) Any Machine Learning Problem Abhishek Thakur, 2020-07-04 This is not a traditional book. The book has a lot of code. If you don't like the code first approach do not buy this book. Making code available on Github is not an option. This book is for people who have some theoretical knowledge of machine learning and deep learning and want to dive into applied machine learning. The book doesn't explain the algorithms but is more oriented towards how and what should you use to solve machine learning and deep learning problems. The book is not for you if you are looking for pure basics. The book is for you if you are looking for guidance on approaching machine learning problems. The book is best enjoyed with a cup of coffee and a laptop/workstation where you can code along. Table of contents: - Setting up your working environment - Supervised vs unsupervised learning - Cross-validation - Evaluation metrics - Arranging machine learning projects - Approaching categorical variables - Feature engineering - Feature selection - Hyperparameter optimization - Approaching image classification & segmentation - Approaching text classification/regression - Approaching ensembling and stacking - Approaching reproducible code & model serving There are no sub-headings. Important terms are written in bold. I will be answering all your queries related to the book and will be making YouTube tutorials to cover what has not been discussed in the book. To ask questions/doubts, visit this link: https://bit.ly/aamlquestions And Subscribe to my youtube channel: https://bit.ly/abhitubesub |
| data science in drug discovery: Machine Learning and Data Science in the Power Generation Industry Patrick Bangert, 2021-01-14 Machine Learning and Data Science in the Power Generation Industry explores current best practices and quantifies the value-add in developing data-oriented computational programs in the power industry, with a particular focus on thoughtfully chosen real-world case studies. It provides a set of realistic pathways for organizations seeking to develop machine learning methods, with a discussion on data selection and curation as well as organizational implementation in terms of staffing and continuing operationalization. It articulates a body of case study–driven best practices, including renewable energy sources, the smart grid, and the finances around spot markets, and forecasting. - Provides best practices on how to design and set up ML projects in power systems, including all nontechnological aspects necessary to be successful - Explores implementation pathways, explaining key ML algorithms and approaches as well as the choices that must be made, how to make them, what outcomes may be expected, and how the data must be prepared for them - Determines the specific data needs for the collection, processing, and operationalization of data within machine learning algorithms for power systems - Accompanied by numerous supporting real-world case studies, providing practical evidence of both best practices and potential pitfalls |
| data science in drug discovery: Artificial Intelligence in Drug Design Alexander Heifetz, 2022-11-05 This volume looks at applications of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in drug design. The chapters in this book describe how AI/ML/DL approaches can be applied to accelerate and revolutionize traditional drug design approaches such as: structure- and ligand-based, augmented and multi-objective de novo drug design, SAR and big data analysis, prediction of binding/activity, ADMET, pharmacokinetics and drug-target residence time, precision medicine and selection of favorable chemical synthetic routes. How broadly are these approaches applied and where do they maximally impact productivity today and potentially in the near future. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary software and tools, step-by-step, readily reproducible modeling protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and unique, Artificial Intelligence in Drug Design is a valuable resource for structural and molecular biologists, computational and medicinal chemists, pharmacologists and drug designers. |
| data science in drug discovery: Rare Disease Drug Development Raymond A. Huml, 2021-11-08 This book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients. A unique reference, the book begins with narratives on the many challenges faced by rare disease patient and their caregivers. Subsequent chapters underscore the critical, multidimensional role of patient advocacy groups and the novel approaches to related clinical trials, investment decisions, and the optimization of rare disease registries. The book addresses various rare disease drug development processes by disciplines such as oncology, hematology, pediatrics, and gene therapy. Chapters then address the operational aspects of drug development, including approval processes, development accelerations, and market access strategies. The book concludes with reflections on the authors' case for real-world data and evidence generation in orphan medicinal drug development. Rare Disease Drug Development is an expertly written text optimized for biopharmaceutical R&D experts, commercial experts, third-party capital providers, patient advocacy groups, patients, and caregivers. |
| data science in drug discovery: Drug Discovery Walter Sneader, 2005-10-31 Written by a leading authority with an excellent reputation and ability for writing a good narrative, Drug Discovery: A History is a far cry from simply a list of chemical structures. This lively new text considers the origins, development and history of medicines that generate high media interest and have a huge social and economic impact on society. Set within a wide historical, social and cultural context, it provides expanded coverage of pre-twentieth century drugs, the huge advances made in the twentieth century and the latest developments in drug research. Hallmark features: Up-to-the-minute information in drug research Vignettes of special and unusual information, and anecdotes Discusses drug prototypes from all sources More comprehensive than other volumes on history of drug discovery From the reviews: ...an excellent bibliographic resource for those interested in the background papers that serve as the foundation for discovery of specific drug entities. JOURNAL OF MEDICAL CHEMISTRY, June 2006 ...a very comprehensive overview of drug development. It should be on the shelf on any aspiring pharmacist, medicinal chemist, or person interested in the history of therapeutic agents. JOURNAL OF CHEMICAL EDUCATION, February 2006 ...a very readable and closely researched book... CHEMISTRY & INDUSTRY, October 2005 |
| data science in drug discovery: Biomarkers in Drug Development Michael R. Bleavins, Claudio Carini, Mallé Jurima-Romet, Ramin Rahbari, 2011-09-20 Discover how biomarkers can boost the success rate of drug development efforts As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in translational medicine and the drug development process. Filled with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine. Biomarkers in Drug Development is divided into eight parts: Part One offers an overview of biomarkers and their role in drug development. Part Two highlights important technologies to help researchers identify new biomarkers. Part Three examines the characterization and validation process for both drugs and diagnostics, and provides practical advice on appropriate statistical methods to ensure that biomarkers fulfill their intended purpose. Parts Four through Six examine the application of biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine. Part Seven focuses on lessons learned and the practical aspects of implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including data integration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or more leading experts, including scientists from biotechnology and pharmaceutical firms, academia, and the U.S. Food and Drug Administration. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development. |
| data science in drug discovery: Data Science Vijay Kotu, Bala Deshpande, 2018-11-27 Learn the basics of Data Science through an easy to understand conceptual framework and immediately practice using RapidMiner platform. Whether you are brand new to data science or working on your tenth project, this book will show you how to analyze data, uncover hidden patterns and relationships to aid important decisions and predictions. Data Science has become an essential tool to extract value from data for any organization that collects, stores and processes data as part of its operations. This book is ideal for business users, data analysts, business analysts, engineers, and analytics professionals and for anyone who works with data. You'll be able to: - Gain the necessary knowledge of different data science techniques to extract value from data. - Master the concepts and inner workings of 30 commonly used powerful data science algorithms. - Implement step-by-step data science process using using RapidMiner, an open source GUI based data science platform Data Science techniques covered: Exploratory data analysis, Visualization, Decision trees, Rule induction, k-nearest neighbors, Naïve Bayesian classifiers, Artificial neural networks, Deep learning, Support vector machines, Ensemble models, Random forests, Regression, Recommendation engines, Association analysis, K-Means and Density based clustering, Self organizing maps, Text mining, Time series forecasting, Anomaly detection, Feature selection and more... - Contains fully updated content on data science, including tactics on how to mine business data for information - Presents simple explanations for over twenty powerful data science techniques - Enables the practical use of data science algorithms without the need for programming - Demonstrates processes with practical use cases - Introduces each algorithm or technique and explains the workings of a data science algorithm in plain language - Describes the commonly used setup options for the open source tool RapidMiner |
| data science in drug discovery: Artificial Intelligence in Healthcare Adam Bohr, Kaveh Memarzadeh, 2020-06-21 Artificial Intelligence (AI) in Healthcare is more than a comprehensive introduction to artificial intelligence as a tool in the generation and analysis of healthcare data. The book is split into two sections where the first section describes the current healthcare challenges and the rise of AI in this arena. The ten following chapters are written by specialists in each area, covering the whole healthcare ecosystem. First, the AI applications in drug design and drug development are presented followed by its applications in the field of cancer diagnostics, treatment and medical imaging. Subsequently, the application of AI in medical devices and surgery are covered as well as remote patient monitoring. Finally, the book dives into the topics of security, privacy, information sharing, health insurances and legal aspects of AI in healthcare. - Highlights different data techniques in healthcare data analysis, including machine learning and data mining - Illustrates different applications and challenges across the design, implementation and management of intelligent systems and healthcare data networks - Includes applications and case studies across all areas of AI in healthcare data |
| data science in drug discovery: Strategies in Biomedical Data Science Jay A. Etchings, 2016-12-27 An essential guide to healthcare data problems, sources, and solutions Strategies in Biomedical Data Science provides medical professionals with much-needed guidance toward managing the increasing deluge of healthcare data. Beginning with a look at our current top-down methodologies, this book demonstrates the ways in which both technological development and more effective use of current resources can better serve both patient and payer. The discussion explores the aggregation of disparate data sources, current analytics and toolsets, the growing necessity of smart bioinformatics, and more as data science and biomedical science grow increasingly intertwined. You'll dig into the unknown challenges that come along with every advance, and explore the ways in which healthcare data management and technology will inform medicine, politics, and research in the not-so-distant future. Real-world use cases and clear examples are featured throughout, and coverage of data sources, problems, and potential mitigations provides necessary insight for forward-looking healthcare professionals. Big Data has been a topic of discussion for some time, with much attention focused on problems and management issues surrounding truly staggering amounts of data. This book offers a lifeline through the tsunami of healthcare data, to help the medical community turn their data management problem into a solution. Consider the data challenges personalized medicine entails Explore the available advanced analytic resources and tools Learn how bioinformatics as a service is quickly becoming reality Examine the future of IOT and the deluge of personal device data The sheer amount of healthcare data being generated will only increase as both biomedical research and clinical practice trend toward individualized, patient-specific care. Strategies in Biomedical Data Science provides expert insight into the kind of robust data management that is becoming increasingly critical as healthcare evolves. |
| data science in drug discovery: GAMP 5 Sion Wyn, 2008 GAMP 5 provides pragmatic and practical industry guidance to achieve compliant computerized systems fit for intended use in an efficient and effective manner. This technical document describes a flexible risk-based approach to compliant GxP regulated computerized systems, based on scalable specification and verification. It points to the future of computer systems compliance by centering on principles behind major industry developments such as PQLI; ICH Q8, Q9, Q10; and ASTM E2500. This revolutionary Guide addresses the entire lifecycle of an automated system and its applicability to a wide range of information systems, lab equipment, integrated manufacturing systems, and IT infrastructures. It contains new information on outsourcing, electronic batch recording, end user applications (such as spreadsheets and small database applications), and patch management. |
| data science in drug discovery: Biophysical and Computational Tools in Drug Discovery Anil Kumar Saxena, 2021-10-18 This book reviews recent physicochemical and biophysical techniques applied in drug discovery research, and it outlines the latest advances in computational drug design. Divided into 10 chapters, the book discusses about the role of structural biology in drug discovery, and offers useful application cases of several biophysical and computational methods, including time-resolved fluorometry (TRF) with Förster resonance energy transfer (FRET), X-Ray crystallography, nuclear magnetic resonance spectroscopy, mass spectroscopy, generative machine learning for inverse molecular design, quantum mechanics/molecular mechanics (QM/MM,ONIOM) and quantum molecular dynamics (QMT) methods. Particular attention is given to computational search techniques applied to peptide vaccines using novel mathematical descriptors and structure and ligand-based virtual screening techniques in drug discovery research. Given its scope, the book is a valuable resource for students, researchers and professionals from pharmaceutical industry interested in drug design and discovery. |
| data science in drug discovery: Pharmaceutical Data Mining Konstantin V. Balakin, 2009-11-19 Leading experts illustrate how sophisticated computational data mining techniques can impact contemporary drug discovery and development In the era of post-genomic drug development, extracting and applying knowledge from chemical, biological, and clinical data is one of the greatest challenges facing the pharmaceutical industry. Pharmaceutical Data Mining brings together contributions from leading academic and industrial scientists, who address both the implementation of new data mining technologies and application issues in the industry. This accessible, comprehensive collection discusses important theoretical and practical aspects of pharmaceutical data mining, focusing on diverse approaches for drug discovery—including chemogenomics, toxicogenomics, and individual drug response prediction. The five main sections of this volume cover: A general overview of the discipline, from its foundations to contemporary industrial applications Chemoinformatics-based applications Bioinformatics-based applications Data mining methods in clinical development Data mining algorithms, technologies, and software tools, with emphasis on advanced algorithms and software that are currently used in the industry or represent promising approaches In one concentrated reference, Pharmaceutical Data Mining reveals the role and possibilities of these sophisticated techniques in contemporary drug discovery and development. It is ideal for graduate-level courses covering pharmaceutical science, computational chemistry, and bioinformatics. In addition, it provides insight to pharmaceutical scientists, principal investigators, principal scientists, research directors, and all scientists working in the field of drug discovery and development and associated industries. |
| data science in drug discovery: Bad Pharma Ben Goldacre, 2014-04 Originally published in 2012, revised edition published in 2013, by Fourth Estate, Great Britain; Published in the United States in 2012, revised edition also, by Faber and Faber, Inc. |
| data science in drug discovery: Bioinformatics and Computational Biology in Drug Discovery and Development William T. Loging, 2016-03-17 A comprehensive overview of the use of computational biology approaches in the drug discovery and development process. |
| data science in drug discovery: De novo Molecular Design Gisbert Schneider, 2013-10-10 Systematically examining current methods and strategies, this ready reference covers a wide range of molecular structures, from organic-chemical drugs to peptides, Proteins and nucleic acids, in line with emerging new drug classes derived from biomacromolecules. A leader in the field and one of the pioneers of this young discipline has assembled here the most prominent experts from across the world to provide first-hand knowledge. While most of their methods and examples come from the area of pharmaceutical discovery and development, the approaches are equally applicable for chemical probes and diagnostics, pesticides, and any other molecule designed to interact with a biological system. Numerous images and screenshots illustrate the many examples and method descriptions. With its broad and balanced coverage, this will be the firststop resource not only for medicinal chemists, biochemists and biotechnologists, but equally for bioinformaticians and molecular designers for many years to come. From the content: * Reaction-driven de novo design * Adaptive methods in molecular design * Design of ligands against multitarget profiles * Free energy methods in ligand design * Fragment-based de novo design * Automated design of focused and target family-oriented compound libraries * Molecular de novo design by nature-inspired computing * 3D QSAR approaches to de novo drug design * Bioisosteres in de novo design * De novo design of peptides, proteins and nucleic acid structures, including RNA aptamers and many more. |
| data science in drug discovery: Human Genome Informatics Christophe Lambert, Darrol Baker, George P. Patrinos, 2018-08-02 Human Genome Informatics: Translating Genes into Health examines the most commonly used electronic tools for translating genomic information into clinically meaningful formats. By analyzing and comparing interpretation methods of whole genome data, the book discusses the possibilities of their application in genomic and translational medicine. Topics such as electronic decision-making tools, translation algorithms, interpretation and translation of whole genome data for rare diseases are thoroughly explored. In addition, discussions of current human genome databases and the possibilities of big data in genomic medicine are presented. With an updated approach on recent techniques and current human genomic databases, the book is a valuable source for students and researchers in genome and medical informatics. It is also ideal for workers in the bioinformatics industry who are interested in recent developments in the field. - Provides an overview of the most commonly used electronic tools to translate genomic information - Brings an update on the existing human genomic databases that directly impact genome interpretation - Summarizes and comparatively analyzes interpretation methods of whole genome data and their application in genomic medicine |
| data science in drug discovery: Data Science for Genomics Amit Kumar Tyagi, Ajith Abraham, 2022-11-27 Data Science for Genomics presents the foundational concepts of data science as they pertain to genomics, encompassing the process of inspecting, cleaning, transforming, and modeling data with the goal of discovering useful information, suggesting conclusions and supporting decision-making. Sections cover Data Science, Machine Learning, Deep Learning, data analysis, and visualization techniques. The authors then present the fundamentals of Genomics, Genetics, Transcriptomes and Proteomes as basic concepts of molecular biology, along with DNA and key features of the human genome, as well as the genomes of eukaryotes and prokaryotes. Techniques that are more specifically used for studying genomes are then described in the order in which they are used in a genome project, including methods for constructing genetic and physical maps. DNA sequencing methodology and the strategies used to assemble a contiguous genome sequence and methods for identifying genes in a genome sequence and determining the functions of those genes in the cell. Readers will learn how the information contained in the genome is released and made available to the cell, as well as methods centered on cloning and PCR. - Provides a detailed explanation of data science concepts, methods and algorithms, all reinforced by practical examples that are applied to genomics - Presents a roadmap of future trends suitable for innovative Data Science research and practice - Includes topics such as Blockchain technology for securing data at end user/server side - Presents real world case studies, open issues and challenges faced in Genomics, including future research directions and a separate chapter for Ethical Concerns |
| data science in drug discovery: AI and data science in drug development and public health: Highlights from the MCBIOS 2022 conference Ramin Homayouni, Prashanti Manda, Aik Choon Tan, Zhaohui Steve Qin, 2023-03-27 |
| data science in drug discovery: Healthcare Data Analytics Chandan K. Reddy, Charu C. Aggarwal, 2015-06-23 At the intersection of computer science and healthcare, data analytics has emerged as a promising tool for solving problems across many healthcare-related disciplines. Supplying a comprehensive overview of recent healthcare analytics research, Healthcare Data Analytics provides a clear understanding of the analytical techniques currently available |
| data science in drug discovery: Sharing Clinical Research Data Institute of Medicine, Board on Health Care Services, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, National Cancer Policy Forum, Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, 2013-06-07 Pharmaceutical companies, academic researchers, and government agencies such as the Food and Drug Administration and the National Institutes of Health all possess large quantities of clinical research data. If these data were shared more widely within and across sectors, the resulting research advances derived from data pooling and analysis could improve public health, enhance patient safety, and spur drug development. Data sharing can also increase public trust in clinical trials and conclusions derived from them by lending transparency to the clinical research process. Much of this information, however, is never shared. Retention of clinical research data by investigators and within organizations may represent lost opportunities in biomedical research. Despite the potential benefits that could be accrued from pooling and analysis of shared data, barriers to data sharing faced by researchers in industry include concerns about data mining, erroneous secondary analyses of data, and unwarranted litigation, as well as a desire to protect confidential commercial information. Academic partners face significant cultural barriers to sharing data and participating in longer term collaborative efforts that stem from a desire to protect intellectual autonomy and a career advancement system built on priority of publication and citation requirements. Some barriers, like the need to protect patient privacy, pre- sent challenges for both sectors. Looking ahead, there are also a number of technical challenges to be faced in analyzing potentially large and heterogeneous datasets. This public workshop focused on strategies to facilitate sharing of clinical research data in order to advance scientific knowledge and public health. While the workshop focused on sharing of data from preplanned interventional studies of human subjects, models and projects involving sharing of other clinical data types were considered to the extent that they provided lessons learned and best practices. The workshop objectives were to examine the benefits of sharing of clinical research data from all sectors and among these sectors, including, for example: benefits to the research and development enterprise and benefits to the analysis of safety and efficacy. Sharing Clinical Research Data: Workshop Summary identifies barriers and challenges to sharing clinical research data, explores strategies to address these barriers and challenges, including identifying priority actions and low-hanging fruit opportunities, and discusses strategies for using these potentially large datasets to facilitate scientific and public health advances. |
Data and Digital Outputs Management Plan (DDOMP)
Data and Digital Outputs Management Plan (DDOMP)
Building New Tools for Data Sharing and Reuse through a …
Jan 10, 2019 · The SEI CRA will closely link research thinking and technological innovation toward accelerating the full path of discovery-driven data use and open science. This will enable a …
Open Data Policy and Principles - Belmont Forum
The data policy includes the following principles: Data should be: Discoverable through catalogues and search engines; Accessible as open data by default, and made available with …
Belmont Forum Adopts Open Data Principles for Environmental …
Jan 27, 2016 · Adoption of the open data policy and principles is one of five recommendations in A Place to Stand: e-Infrastructures and Data Management for Global Change Research, …
Belmont Forum Data Accessibility Statement and Policy
The DAS encourages researchers to plan for the longevity, reusability, and stability of the data attached to their research publications and results. Access to data promotes reproducibility, …
Climate-Induced Migration in Africa and Beyond: Big Data and …
CLIMB will also leverage earth observation and social media data, and combine them with survey and official statistical data. This holistic approach will allow us to analyze migration process …
Advancing Resilience in Low Income Housing Using Climate …
Jun 4, 2020 · Environmental sustainability and public health considerations will be included. Machine Learning and Big Data Analytics will be used to identify optimal disaster resilient …
Belmont Forum
What is the Belmont Forum? The Belmont Forum is an international partnership that mobilizes funding of environmental change research and accelerates its delivery to remove critical …
Waterproofing Data: Engaging Stakeholders in Sustainable Flood …
Apr 26, 2018 · Waterproofing Data investigates the governance of water-related risks, with a focus on social and cultural aspects of data practices. Typically, data flows up from local levels to …
Data Management Annex (Version 1.4) - Belmont Forum
A full Data Management Plan (DMP) for an awarded Belmont Forum CRA project is a living, actively updated document that describes the data management life cycle for the data to be …
Data and Digital Outputs Management Plan (DDOMP)
Data and Digital Outputs Management Plan (DDOMP)
Building New Tools for Data Sharing and Reuse through a …
Jan 10, 2019 · The SEI CRA will closely link research thinking and technological innovation toward accelerating the full path of discovery-driven data use and open science. This will enable a …
Open Data Policy and Principles - Belmont Forum
The data policy includes the following principles: Data should be: Discoverable through catalogues and search engines; Accessible as open data by default, and made available with …
Belmont Forum Adopts Open Data Principles for Environmental …
Jan 27, 2016 · Adoption of the open data policy and principles is one of five recommendations in A Place to Stand: e-Infrastructures and Data Management for Global Change Research, …
Belmont Forum Data Accessibility Statement and Policy
The DAS encourages researchers to plan for the longevity, reusability, and stability of the data attached to their research publications and results. Access to data promotes reproducibility, …
Climate-Induced Migration in Africa and Beyond: Big Data and …
CLIMB will also leverage earth observation and social media data, and combine them with survey and official statistical data. This holistic approach will allow us to analyze migration process …
Advancing Resilience in Low Income Housing Using Climate …
Jun 4, 2020 · Environmental sustainability and public health considerations will be included. Machine Learning and Big Data Analytics will be used to identify optimal disaster resilient …
Belmont Forum
What is the Belmont Forum? The Belmont Forum is an international partnership that mobilizes funding of environmental change research and accelerates its delivery to remove critical …
Waterproofing Data: Engaging Stakeholders in Sustainable Flood …
Apr 26, 2018 · Waterproofing Data investigates the governance of water-related risks, with a focus on social and cultural aspects of data practices. Typically, data flows up from local levels to …
Data Management Annex (Version 1.4) - Belmont Forum
A full Data Management Plan (DMP) for an awarded Belmont Forum CRA project is a living, actively updated document that describes the data management life cycle for the data to be …
